This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Livermore, D. M.
Right arrow Articles by Woodford, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, D. M.
Right arrow Articles by Woodford, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1112-1114, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01347-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci{triangledown}

David M. Livermore,* Marina Warner, Shazad Mushtaq, Sarah North,{dagger} and Neil Woodford

Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom

Received 27 October 2006/ Returned for modification 13 December 2006/ Accepted 24 December 2006

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 µg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 µg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 µg/ml, versus linezolid MICs of 8 to 64 µg/ml; actual values reflected the proportion of gene copies mutated.

* Corresponding author. Mailing address: Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom. Phone: 44 (0) 20-8327-7223. Fax: 44 (0) 8327-6264. E-mail: david.livermore{at}hpa.org.uk.

{triangledown} Published ahead of print on 8 January 2007.

{dagger} Present address: Veterinary Laboratories Agency Weybridge, Technology Transfer Unit, New Haw, Addlestone, Surrey KT15 3NB, United Kingdom.

Antimicrobial Agents and Chemotherapy, March 2007, p. 1112-1114, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01347-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Liakopoulos, A., Neocleous, C., Klapsa, D., Kanellopoulou, M., Spiliopoulou, I., Mathiopoulos, K. D., Papafrangas, E., Petinaki, E. (2009). A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis. J Antimicrob Chemother 64: 206-207 [Full Text]  
  • Hilliard, J. J., Fernandez, J., Melton, J., Macielag, M. J., Goldschmidt, R., Bush, K., Abbanat, D. (2009). In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 53: 2028-2033 [Abstract] [Full Text]  
  • Kalia, V., Miglani, R., Purnapatre, K. P., Mathur, T., Singhal, S., Khan, S., Voleti, S. R., Upadhyay, D. J., Saini, K. S., Rattan, A., Raj, V. S. (2009). Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes. Antimicrob. Agents Chemother. 53: 1427-1433 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»